A Molecular Psychiatry review shows that depression in Alzheimer’s and Parkinson’s disease may reflect disease-specific molecular, neurotransmitter, inflammatory, and circuit-level disruptions rather than standard depression biology alone. It argues that broad antidepressants often show limited efficacy in these patients and that future trials should use biomarkers, neuroimaging, and symptom profiling to guide targeted treatments.